Le Lézard
Classified in: Health
Subjects: POL, PSF, CFG

Health Canada proposes new regulations linked to Vanessa's Law to further strengthen the safety and surveillance of drugs and medical devices


The proposed regulations will improve the reporting of serious adverse drug reactions and medical device incidents by hospitals

OTTAWA, June 15, 2018 /CNW/ - Adverse reactions to drugs and incidents involving medical devices account for many hospital admissions and emergency room visits in Canada every year. These serious adverse drug reactions and medical device incidents are significantly underreported by clinicians, which is a long-standing problem both in Canada and internationally.

Today, Health Canada published proposed regulations in Canada Gazette, Part I to amend the Food and Drug Regulations and Medical Devices Regulations to require hospitals to report serious adverse drug reactions and medical device incidents. This regulatory proposal supports authorities gained through the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law).

 Under the proposed regulations, hospitals will be required to report to Health Canada all serious adverse drug reactions and medical device incidents, in writing, within 30 days of when the incident was first documented within the hospital. The proposed regulations aim to improve the quality and increase the quantity of serious adverse drug reaction and medical device incident reports provided to Health Canada.

Such reports are important in managing the risks associated with the use of drugs and medical devices, and are often the first sign of emerging safety problems. This new reporting requirement will help Health Canada better understand the benefits and harms of marketed health products, which will contribute to improving the safety of drugs and medical devices used by Canadians.

These new measures are part of the Government of Canada's efforts to gather important safety information and to take necessary action, while minimizing impacts on hospitals and on the health care system.

The proposed regulations are based on the feedback that Health Canada received during its consultations to date. Canadians and stakeholders are invited to provide comments on the regulatory proposal between June 16 and August 29, 2018.

Quotes

"Our Government is continuously looking for ways to strengthen product safety to help ensure better health outcomes for Canadians. Improved reporting will allow Health Canada to take action much more quickly against products that may pose a risk to the health and safety of Canadians."

The Honourable Ginette Petitpas Taylor
Minister of Health

Quick Facts

Related Products

Consultation: mandatory reporting of serious adverse drug reactions and medical device incidents 
What we heard ? Responses to the public consultation paper entitled Toward mandatory reporting of serious adverse drug reactions and medical device incidents by health care institutions 
Regulatory Initiative: Regulations amending the Food and Drug Regulations and Medical Device Regulations (Vanessa's Law) 
Protecting Canadians from Unsafe Drugs Act (Vanessa's Law): Questions/Answers

 

SOURCE Health Canada


These press releases may also interest you

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...



News published on and distributed by: